AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Quarter Return
-2.91%
1 Year Return
+18.84%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$136M
AUM Growth
+$136M
(-18%)
Cap. Flow
-$37.2M
Cap. Flow
% of AUM
-27.37%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
262
New
34
Increased
55
Reduced
87
Closed
45
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$1.14M |
| 2 |
Invesco QQQ Trust
QQQ
|
$1.02M |
| 3 |
Invesco NASDAQ 100 ETF
QQQM
|
$1.02M |
| 4 |
Amphastar Pharmaceuticals
AMPH
|
$1M |
| 5 |
Enovis
ENOV
|
$904K |
Top Sells
| 1 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$2.31M |
| 2 |
UroGen Pharma
URGN
|
$2.16M |
| 3 |
Corcept Therapeutics
CORT
|
$2.14M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$1.5M |
| 5 |
Axsome Therapeutics
AXSM
|
$1.41M |
Sector Composition
| 1 | Healthcare | 60.25% |
| 2 | Real Estate | 12.98% |
| 3 | Financials | 6.42% |
| 4 | Industrials | 2.59% |
| 5 | Technology | 2.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Invesco NASDAQ 100 ETF
QQQM
$58.7B
| $1.56M | 1.15% |
7,899
+5,159
| +188% | +$1.02M |
|
27
Dynavax Technologies
DVAX
$1.19B
| $1.46M | 1.08% |
130,000
+7,500
| +6% | +$84.2K |
|
|
MITT
28
AG Mortgage Investment Trust
MITT
$245M
| $1.39M | 1.02% |
208,879
| – | – |
|
29
Medtronic
MDT
$118B
| $1.38M | 1.01% |
17,500
-3,000
| -15% | -$236K |
|
|
ITCI
30
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.37M | 1.01% |
20,000
| – | – |
|
31
BioMarin Pharmaceuticals
BMRN
$11.3B
| $1.36M | 1% |
16,500
+1,000
| +6% | +$82.3K |
|
32
GSK
GSK
$79.3B
| $1.35M | 0.99% |
35,000
| – | – |
|
33
Equity Lifestyle Properties
ELS
$11.7B
| $1.34M | 0.99% |
20,611
| – | – |
|
34
Enact Holdings
ACT
$5.57B
| $1.3M | 0.96% |
42,367
| – | – |
|
35
Exact Sciences
EXAS
$9.33B
| $1.27M | 0.93% |
30,000
+1,000
| +3% | +$42.3K |
|
|
BCYC
36
Bicycle Therapeutics
BCYC
$492M
| $1.21M | 0.89% |
60,000
| – | – |
|
|
37
Axsome Therapeutics
AXSM
$6.09B
| $1.21M | 0.89% |
15,000
-17,500
| -54% | -$1.41M |
|
38
Synopsys
SNPS
$110B
| $1.19M | 0.88% |
2,000
-500
| -20% | -$298K |
|
|
39
Sarepta Therapeutics
SRPT
$1.98B
| $1.19M | 0.87% |
7,500
+7,231
| +2,688% | +$1.14M |
|
40
Jazz Pharmaceuticals
JAZZ
$7.99B
| $1.17M | 0.86% |
11,000
+2,500
| +29% | +$267K |
|
|
NYMT
41
New York Mortgage Trust
NYMT
$642M
| $1.17M | 0.86% |
200,963
| – | – |
|
42
Stereotaxis
STXS
$246M
| $1.09M | 0.8% |
600,000
| – | – |
|
43
Structure Therapeutics
GPCR
$1.14B
| $1.02M | 0.75% |
26,000
-1,500
| -5% | -$58.9K |
|
|
44
Amphastar Pharmaceuticals
AMPH
$1.37B
| $1M | 0.74% |
+25,000
| New | +$1M |
|
45
Karyopharm Therapeutics
KPTI
$61.4M
| $976K | 0.72% |
1,125,000
| – | – |
|
46
Tourmaline Bio
TRML
$645M
| $965K | 0.71% |
75,000
+13,900
| +23% | +$179K |
|
47
Neurocrine Biosciences
NBIX
$13.5B
| $964K | 0.71% |
7,000
| – | – |
|
48
Immunovant
IMVT
$2.91B
| $964K | 0.71% |
36,500
-1,500
| -4% | -$39.6K |
|
49
Roivant Sciences
ROIV
$8.6B
| $930K | 0.68% |
88,000
-2,000
| -2% | -$21.1K |
|
|
50
Enovis
ENOV
$1.75B
| $904K | 0.67% |
+20,000
| New | +$904K |
|